Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023)

Historic Change in Receivables for SAB Biotherapeutics (SABS) over the last 3 years, with Q3 2023 value amounting to -$361735.0.

  • SAB Biotherapeutics' Change in Receivables fell 11086.5% to -$361735.0 in Q3 2023 from the same period last year, while for Dec 2023 it was -$5.6 million, marking a year-over-year decrease of 12641.73%. This contributed to the annual value of -$5.6 million for FY2023, which is 12641.73% down from last year.
  • According to the latest figures from Q3 2023, SAB Biotherapeutics' Change in Receivables is -$361735.0, which was down 11086.5% from -$401388.0 recorded in Q2 2023.
  • In the past 5 years, SAB Biotherapeutics' Change in Receivables ranged from a high of $5.5 million in Q2 2021 and a low of -$9.0 million during Q1 2021
  • For the 3-year period, SAB Biotherapeutics' Change in Receivables averaged around -$1.9 million, with its median value being -$2.2 million (2022).
  • The largest annual percentage gain for SAB Biotherapeutics' Change in Receivables in the last 5 years was 14828.4% (2022), contrasted with its biggest fall of 23532.02% (2022).
  • Quarter analysis of 3 years shows SAB Biotherapeutics' Change in Receivables stood at -$2.2 million in 2021, then plummeted by 235.32% to -$7.4 million in 2022, then soared by 95.1% to -$361735.0 in 2023.
  • Its Change in Receivables was -$361735.0 in Q3 2023, compared to -$401388.0 in Q2 2023 and -$4.8 million in Q1 2023.